Addition of zoledronic acid to neoadjuvant chemotherapy is not beneficial in patients with HER2-negative stage II/III breast cancer: 5-year survival analysis of the NEOZOTAC trial (BOOG 2010-01)

Thumbnail
Fulltext:
207351.pdf
Size:
1.030Mb
Format:
PDF
Description:
Publisher’s version
Download
Publication year
2019
Author(s)
Groot, S. de
Pijl, H.
Charehbili, A.
Ven, S. van de
Smit, V.T.
Meershoek-Klein Kranenbarg, Elma
Laarhoven, H.W.M. van
Hoeven, J.J.M. van der
Nortier, J.W.
Kroep, Judith R.
Source
Breast Cancer Research, 21, 1, (2019), article 97
ISSN
DOI
Publication type
Article / Letter to editor
Please use this identifier to cite or link to this item: https://hdl.handle.net/2066/207351   https://hdl.handle.net/2066/207351
Display more details

Upload full text

Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.